Open AccessCNOT4 enhances the efficacy of anti‐PD‐1 immunotherapy in a model of non‐small cell lung cancer
Author(s) -
Zhang Biao,
Han Song,
Ma Haitao,
Chen Shaomu
Publication year - 2020
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12998
Subject(s) - immunotherapy , medicine , lung cancer , cd8 , cancer research , oncology , pd l1 , interferon , immune system , cancer , immunology
CNOT4 was observed to be positively associated with relapse‐free survival and overall survival in patients with NSCLC. CNOT4 may enhance the efficacy of anti‐PD‐1 immunotherapy and may have potential as a prognostic marker for NSCLC, or as a combinational target with anti‐PD‐1 treatment for patients with NSCLC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom